Form 8-K - Current report:
SEC Accession No. 0001193125-26-227921
Filing Date
2026-05-18
Accepted
2026-05-18 08:00:43
Documents
10
Period of Report
2026-05-18
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tcrt-20260302.htm   iXBRL 8-K 58088
2 EX-99.1 tcrt-ex99_1.htm EX-99.1 21898
  Complete submission text file 0001193125-26-227921.txt   195967

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20260302.xsd EX-101.SCH 27376
14 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20260302_htm.xml XML 4720
Mailing Address 501 E LAS OLAS BLVD SUITE 300 FORT LAUDERDALE FL 33301
Business Address 501 E LAS OLAS BLVD SUITE 300 FORT LAUDERDALE FL 33301 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 26990829
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)